Visiox Pharmaceuticals Announces Definitive Merger With Ocuvex Therapeutics

Tarsus Pharmaceuticals Acquires iRenix Medical to Advance IRX-101 for Retina Care

July 9, 2026

Biotechnology

Tarsus Pharmaceuticals announced it has acquired iRenix Medical, adding late-stage investigational ocular antiseptic IRX-101 to its eye care pipeline. Under the agreement, Tarsus will pay about $75 million upfront (cash and stock) and make additional regulatory and commercial milestone payments up to $490 million.

Lupin Acquires VISUfarma from GHO Capital

September 29, 2025

Healthcare Services

Lupin Limited, through its wholly owned subsidiary Nanomi B.V., signed a definitive agreement to acquire VISUfarma B.V. from healthcare investor GHO Capital Partners LLP. The acquisition expands Lupin’s specialty ophthalmology franchise by adding a portfolio of 60+ branded eye health products and established commercial operations across major European markets.

Azurity Pharmaceuticals Acquires Covis Pharma

March 14, 2025

Pharmaceuticals

Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.

Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline

December 12, 2024

Biotechnology

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.

Cooper Consumer Health Acquires Viatris' Over-the-Counter Business

July 3, 2024

Pharmaceuticals

Cooper Consumer Health has completed the acquisition of the Over-the-Counter (OTC) business of Viatris Inc., following regulatory approvals and worker council consultations. The deal brings more than 200 brands (including Betadine, Saugella, Armolipid and CB12), two manufacturing sites in Mérignac (France) and Confienza (Italy) and an R&D centre in Monza (Italy) into Cooper's platform, doubling Cooper's revenues to approximately €1.2bn.

Nicox S.A. Acquires Aciex Therapeutics, Inc.

July 2, 2014

Pharmaceuticals

Nicox S.A. agreed to acquire Aciex Therapeutics, Inc., a U.S.-based ophthalmic development company, in a share-exchange deal that will transfer 100% of Aciex to Nicox. The transaction (approved by Nicox shareholders on October 22, 2014) issues 20,627,024 new Nicox shares for Aciex equity and includes contingent value rights giving up to $55 million in potential additional consideration tied to FDA approvals, and is intended to broaden Nicox's ophthalmic development pipeline.